These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 20028851)
1. The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer. Gallí M; Van Gool F; Rongvaux A; Andris F; Leo O Cancer Res; 2010 Jan; 70(1):8-11. PubMed ID: 20028851 [TBL] [Abstract][Full Text] [Related]
2. Nampt and its potential role in inflammation and type 2 diabetes. Garten A; Petzold S; Schuster S; Körner A; Kratzsch J; Kiess W Handb Exp Pharmacol; 2011; (203):147-64. PubMed ID: 21484571 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of nicotinamide phosphoribosyltransferase modifies LPS-induced inflammatory responses of human monocytes. Schilling E; Wehrhahn J; Klein C; Raulien N; Ceglarek U; Hauschildt S Innate Immun; 2012 Jun; 18(3):518-30. PubMed ID: 21975728 [TBL] [Abstract][Full Text] [Related]
4. Nicotinamide phosphoribosyl-transferase/visfatin: a missing link between overweight/obesity and postmenopausal breast cancer? Potential preventive and therapeutic perspectives and challenges. Dalamaga M Med Hypotheses; 2012 Nov; 79(5):617-21. PubMed ID: 22922056 [TBL] [Abstract][Full Text] [Related]
7. Nampt/PBEF/Visfatin: a new player in beta cell physiology and in metabolic diseases? Tanaka T; Nabeshima Y Cell Metab; 2007 Nov; 6(5):341-3. PubMed ID: 17983577 [TBL] [Abstract][Full Text] [Related]
8. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities. Chen H; Wang S; Zhang H; Nice EC; Huang C Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719 [TBL] [Abstract][Full Text] [Related]
9. Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase. Zhang LY; Liu LY; Qie LL; Ling KN; Xu LH; Wang F; Fang SH; Lu YB; Hu H; Wei EQ; Zhang WP Eur J Pharmacol; 2012 Jan; 674(2-3):163-70. PubMed ID: 22119381 [TBL] [Abstract][Full Text] [Related]
10. The role of extracellular and intracellular Nicotinamide phosphoribosyl-transferase in cancer: Diagnostic and therapeutic perspectives and challenges. Dalamaga M; Christodoulatos GS; Mantzoros CS Metabolism; 2018 May; 82():72-87. PubMed ID: 29330025 [TBL] [Abstract][Full Text] [Related]
11. Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience. Montecucco F; Cea M; Bauer I; Soncini D; Caffa I; Lasigliè D; Nahimana A; Uccelli A; Bruzzone S; Nencioni A Curr Drug Targets; 2013 Jun; 14(6):637-43. PubMed ID: 23531116 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review. Gasparrini M; Giovannuzzi S; Nocentini A; Raffaelli N; Supuran CT Expert Opin Ther Pat; 2024 Jul; 34(7):565-582. PubMed ID: 38861278 [TBL] [Abstract][Full Text] [Related]
16. Nicotinamide phosphoribosyltransferase as a target in inflammation- related disorders. Montecucco F; Cea M; Cagnetta A; Damonte P; Nahimana A; Ballestrero A; Del Rio A; Bruzzone S; Nencioni A Curr Top Med Chem; 2013; 13(23):2930-8. PubMed ID: 24171767 [TBL] [Abstract][Full Text] [Related]
17. NAMPT inhibition reduces macrophage inflammation through the NAD+/PARP1 pathway to attenuate liver ischemia-reperfusion injury. Lu J; Wang M; Chen Y; Song H; Wen D; Tu J; Guo Y; Liu Z Chem Biol Interact; 2023 Jan; 369():110294. PubMed ID: 36460127 [TBL] [Abstract][Full Text] [Related]
19. Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Imai S Curr Pharm Des; 2009; 15(1):20-8. PubMed ID: 19149599 [TBL] [Abstract][Full Text] [Related]